Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
13.39
-0.89 (-6.23%)
At close: Jul 24, 2026, 4:00 PM EDT
13.11
-0.28 (-2.09%)
After-hours: Jul 24, 2026, 7:59 PM EDT
Immunic Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
95
Market Cap
182.39M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Protalix BioTherapeutics | 76.38M |
| Cellectis | 75.11M |
| Precision BioSciences | 45.07M |
| Atrium Therapeutics | 36.68M |
| Keros Therapeutics | 33.18M |
| Whitehawk Therapeutics | 7.15M |
| Armata Pharmaceuticals | 5.20M |
IMUX News
- 16 days ago - Immunic to Participate in Investor Conferences in July - PRNewsWire
- 6 weeks ago - Immunic to Participate in Investor, Industry and Scientific Conferences in June - PRNewsWire
- 7 weeks ago - Immunic Slides: Corporate presentation - Filings
- 2 months ago - Immunic Proxy statement: Proxy filing - Filings
- 2 months ago - Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed - TheFly
- 2 months ago - Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - PRNewsWire
- 2 months ago - B. Riley cuts Immunic target, sees ‘compelling entry point’ - TheFly